IS:GLENMARK Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, the United States, Latin America, Europe, and internationally. The company provides branded and generic formulations in therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its products under development comprise GBR 1302 for breast and gastric cancer; GBR 1342 for multiple myeloma; GBR 1372 for colorectal cancer; GBR 8383 for multiple cancers; GBR 830 for atopic dermatitis; GRC 39815 for COPD and IPF; GSP 301 for allergic rhinitis; GSP 304 for COPD; GBR 310 for Asthma and CIU; and GRC 27864 for chronic pain indications. The company was founded in 1977 and is based in Mumbai, India.

482.95 INR
As of 01/21/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Health Care
Industry:  Drug Manufacturers-Specialty &
Index country:  India
Country of incorporation:  India
IPO date:  07/01/2002
Stock exchange:    National Stock Exchange O
Exchange country:   India
Market cap:   136,273,035,264 INR
Current dividend yield:   0.50%
Sedol:      6698755

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy